2006 FDA Process Chemistry Therapies 
Metabolite Tales Blog
JULY 5, 2023
Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Journal of Medicinal Chemistry 62 (21), 9418-9437.
Metabolite Tales Blog
JULY 5, 2023
Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Journal of Medicinal Chemistry 62 (21), 9418-9437.
Expert insights. Personalized for you.
52 
Let's personalize your content